Waldenstrom's Macroglobulinaemia Refractory
Conditions
Brief summary
Waldenström macroglobulinemia (WM) is an incurable disease. BCL2 antagonist, an important anti-apoptosys molecule, is already approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Recently, a clinical trial including 32 patients with WM treated with Venetoclax showed an overall response rates of 84% and a major response rate of 81%. However, there is no in real life data, in the french population, of the efficiency of Venetoclax in WM. The aim of our multicentric retrospective study is to evaluate the efficiency and tolerance of Venetoclax in WM.
Interventions
DRUGVenetoclax
Observational study
Sponsors
Poitiers University Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Waldenstrom's macroglobulinemia * Treatment with Venetoclax * Non opposition
Exclusion criteria
none
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficiency | 2018 to 2025 | ORR, MRR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficiency in specific population | 2018 to 2025 | ORR in CXCR4 mutated patients, ORR in patients previously treated with BTK inhibitors |
| Tolerance | 2018 to 2025 | Adverse events |
Countries
France
Contacts
Primary Contactcécile tomowiak, Dr
Backup ContactMathilde Vonfeld, Intern
Outcome results
None listed